Latest Leverage News

Gold Road Resources reports a robust half-year profit surge driven by higher gold prices and sales, while advancing a proposed acquisition by Gold Fields with a shareholder vote set for September.

Sayona Mining delivered record lithium production and sales in FY25 but reported a $382 million loss due to asset impairments amid falling lithium prices. The company is poised for transformation with its imminent merger with Piedmont Lithium.

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Austal Limited has reported a remarkable 24% revenue increase and a 503% surge in net profit for FY2025, yet has chosen not to declare any dividends for the year.

Atlas Pearls reported increased pearl harvest and sales volumes for FY25, driving revenue growth to $44.3 million, though profits declined compared to the previous year. The company declared a fully franked final dividend, underscoring its solid financial footing.

Cettire Limited reported stable revenue for FY25 despite a challenging luxury market, but profitability sharply declined due to increased promotional activity and softer demand.

MOVE Logistics Group Limited reported a solid FY25 performance with a 61% improvement in normalised earnings despite a challenging economy, setting the stage for a return to profitability in FY26.

Nexion Group has agreed to sell its telecommunications subsidiaries for $4.1 million, aiming to reduce debt and pivot towards its high-growth AI and business intelligence operations.

Atlas Pearls Ltd reported a 6% revenue increase to $44.3 million in FY25 despite a 30% drop in net profit, unveiling a strategic roadmap targeting up to 50% production growth by FY30 alongside a fully franked dividend.

Civmec Limited reported solid FY2025 financials with revenue surpassing A$810 million and a strengthened order book of A$1.25 billion, underpinned by its strategic acquisition of Luerssen Australia.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.